Carbon Streaming将上市市场从OTC升级为OTCQB

多伦多–()–(美国商业资讯)–Carbon Streaming Corporation (NEO: NETZ) (OTCQB: OFSTF) (FSE: M2Q)(简称“Carbon Streaming”或“公司”)欣然宣布,公司已获准在OTCQB市场(“OTCQB”)交易其普通股,交易代码为OFSTF,自2021年11月22日起生效。作为公司增长战略的一部分,从OTC粉单市场升级到OTCQB市场可使更广泛的投资者投资Carbon Streaming。公司的普通股将继续在NEO交易所和法兰克福证券交易所进行交易,交易代码分别为“NETZ”和“M2Q”。

Carbon Streaming首席执行官Justin Cochrane评论道:“Carbon Streaming将继续致力于2022年在美国主板上市,而在我们寻求此类上市的过程中,在OTCQB交易为我们的美国投资者架起了一座桥梁。与此同时,OTCQB平台应有助于扩大我们的美国股东范围,使更广泛的投资者群体能够通过公司现有的高质量投资参与不断增长的全球碳抵消市场。”

OTCQB是由美国场外交易集团(OTC Markets Group)在纽约运营的一个美国交易市场,专为美国和海外的发展中企业和创业型企业设计。要想在OTCQB上市,企业必须提供最新的财务报告,并经过年度验证和管理认证程序,包括满足最低投标价格和其他财务条件。OTCQB具有更高的合规性和质量标准,为投资者提供更广的可视性,以增强交易决策。OTCQB被美国证券交易委员会确认为成熟的公开市场,在证券价值和交易分析方面提供公开信息。

关于Carbon Streaming

Carbon Streaming是一个独特的ESG原则投资工具,可为投资者提供碳信用额度敞口,是政府和企业实现其碳中和与“净零”气候目标的关键工具。我们的商业模式专注于获取、管理和发展高质量、多样化的项目和/或公司投资组合,投资于直接或间接产生或积极参与自愿和/或合规碳信用额的项目和/或公司。








Liberty All-Star® Equity Fund Announces Results of Rights Offering

BOSTON, Nov. 23, 2021 /PRNewswire/ — The Liberty All-Star® Equity Fund (NYSE: USA) today announced that based on results provided by the Fund’s subscription agent its rights offering, which expired on November 22, 2021, was fully subscribed.  The Fund will issue 27,979,915 shares, which represents the entire 22,383,932 primary subscription shares in the offering, plus 5,595,983 additional shares made available by means of the secondary over-subscription privilege. Since there were not sufficient shares to honor all over-subscription requests, available shares will be allocated among those shareholders who over-subscribed based on the number of shares held on the record date.

The Subscription Price per share is $7.78, which represents 95 percent of the net asset value of a share on the Expiration Date.

The Fund does not continuously issue shares and trades in the secondary market. Investors wishing to buy or sell shares need to place orders through an intermediary or broker. The share price of a closed-end fund is based on the market’s value. The Fund’s shares are listed on the NYSE under the ticker symbol USA. ALPS Advisors, Inc. is the investment advisor of the Fund, a multi-managed, closed-end investment company with more than $1.8 billion in net assets as of November 22, 2021.

Past performance cannot predict future results.
An investment in the Fund involves risk, including loss of principal.
Secondary market support provided to the Fund by ALPS Fund Services, Inc.’s affiliate ALPS Portfolio Solutions Distributor, Inc., a FINRA Member. ALPS Fund Services, Inc., ALPS Advisors, Inc. and ALPS Portfolio Solutions Distributor, Inc. are affiliated entities.

For Information Contact:
Liberty All-Star® Equity Fund

SOURCE Liberty All-Star Equity Fund

ViewRay Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Public Offering of Common Stock

CLEVELAND, Nov. 23, 2021 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the closing of an additional 1,875,000 shares of common stock following the exercise in full of the underwriters’ option to purchase additional shares in connection with its recently completed public offering of 12,500,000 shares of common stock, for additional gross proceeds of $10.5 million for total gross proceeds of $80.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay.  All of the shares sold in the offering were sold by ViewRay.  

ViewRay intends to use the net proceeds from the offering for general corporate purposes, including working capital, capital expenditures, continued research and development and commercial expenses.  

Piper Sandler and Stifel acted as the joint book-running managers for the offering.  Guggenheim Securities also acted as a book-running manager for the offering.  B. Riley Securities and BTIG acted as co-managers for the offering.

A registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission (“SEC”) and automatically became effective upon filing.  This offering was made solely by means of a prospectus supplement and accompanying prospectus included in the registration statement.  A final prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC and is available on the SEC’s website located at  Alternatively, copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at [email protected], or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About ViewRay

ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward Looking Statements:

Except for historical information, certain statements in this press release, including statements regarding the anticipated use of proceeds of the public offering,  are forward-looking in nature and are subject to risks, uncertainties and assumptions about us, including, without limitation, risks and uncertainties related to market conditions.  Such forward-looking statements involve substantial risks and uncertainties that relate to future events and the actual results could differ significantly from those expressed or implied by the forward-looking statements.  Any forward-looking statements are based on ViewRay’s current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements.  ViewRay makes no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.  For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay’s business in general, please refer to the “Risk Factors” sections in ViewRay’s final prospectus supplement filed with the SEC on November 18, 2021, including the documents incorporated by reference therein, its Annual Report on Form 10-K filed with the SEC on March 5, 2021, its Quarterly Reports on Form 10-Q filed with the SEC on May 7, 2021, August 6, 2021, and November 5, 2021 and certain of its other reports filed with the SEC.

SOURCE ViewRay, Inc.

RedHill Biopharma Announces Closing of $15.5 Million Public Offering of American Depositary Shares

TEL AVIV, Israel and RALEIGH, N.C., Nov. 23, 2021 /PRNewswire/ — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced the closing of the previously announced underwritten public offering of approximately 4.7 million American Depositary Shares (“ADSs”) for gross proceeds of approximately $15.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by RedHill. Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of the Company. All of the ADSs were offered by RedHill. In addition, RedHill has granted the underwriter a 30-day option to purchase up to approximately an additional 0.7 million ADSs.

Cantor Fitzgerald & Co. acted as sole bookrunner for the offering. SMBC Nikko Securities America, Inc. acted as a financial advisor to the Company.

RedHill intends to use the net proceeds of the offering to fund its commercialization activities, clinical development programs and for acquisitions and general corporate purposes.

The securities described above were offered by RedHill pursuant to a shelf registration statement on Form F-3 (No. 333-232777) declared effective by the Securities and Exchange Commission (the “SEC”) on August 8, 2019.

The final prospectus supplement and the accompanying prospectus relating to the offering was filed with the SEC and is available on the SEC’s website at Alternatively, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Cantor Fitzgerald & Co., 499 Park Avenue, 4th Floor, New York, New York 10022, Attn: Capital Markets Department, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About RedHill Biopharma

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Movantik® for opioid-induced constipation in adults[1]Talicia® for the treatment of Helicobacter pylori (H. pylori) infection in adults[2], and Aemcolo® for the treatment of travelers’ diarrhea in adults[3]. RedHill’s key clinical late-stage development programs include: (i) RHB-204, with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) opaganib (ABC294640), a firstinclass, oral SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-107 (upamostat), an oral serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; (v) RHB-102, with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi) RHB106, an encapsulated bowel preparation.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, delays in obtaining required stock exchange or other regulatory approvals, share price volatility and the impact of general business and economic conditions; the risk that the follow up for Part A and the commencement of Part B of the Phase 2/3 study evaluating RHB-107 in patients with symptomatic COVID-19 will be delayed, not completed or not successful; the risk that RHB-107 and/or opaganib will not be effective against emerging viral variants with mutations in the spike protein; the risk that the Company’s Phase 2/3 development program evaluating RHB-107 and/or opaganib will not be successful and that the data from this clinical study will be delayed, if at all; the risk of a delay in receiving data to support emergency use applications or in making such emergency use applications, if at all; the risk that the Company will not initiate the Phase 2/3 study for RHB-107 in certain geographies, including South Africa, will not expand this study to additional sites in the U.S and that it will not be successful and that enrollment will be delayed; the risk that COVID-19 patients treated with RHB-107 or opaganib will not show any clinical improvement; the development risks of early-stage discovery efforts for a relatively new disease, including difficulty in assessing the efficacy of RHB-107 and opaganib for the treatment of COVID-19, if at all; intense competition from other companies developing potential treatments and vaccines for COVID-19; the effect of a potential occurrence of patients suffering serious adverse events using RHB-107, as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates and Talicia®; (v) the Company’s ability to successfully commercialize and promote Movantik®, Talicia® and Aemcolo®; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build and sustain its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and commercial products and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse events using investigative drugs under the Company’s Expanded Access Program; and (xiv) competition from other companies and technologies within the Company’s industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, including the Company’s Annual Report on Form 20-F filed with the SEC on March 18, 2021. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.


Company contact:

Adi Frish

Chief Corporate & Business Development Officer

RedHill Biopharma


[email protected]

Media contacts:

U.S.: Bryan Gibbs, Finn Partners

+1 212 529 2236

[email protected]

UK: Amber Fennell, Consilium

+44 (0) 7739 658 783

[email protected]

1 Full prescribing information for Movantik® (naloxegol) is available at:

2 Full prescribing information for Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is available at:

3 Full prescribing information for Aemcolo® (rifamycin) is available at:

SOURCE RedHill Biopharma Ltd.

Venture Global anuncia el cierre de bonos sénior garantizados por dólares

– Venture Global anuncia el cierre de bonos sénior garantizados por dólares por parte de Venture Global Calcasieu Pass, LLC

ARLINGTON, Va., 23 de noviembre, 2021 /PRNewswire/ —  Venture Global LNG, Inc. (“Venture Global”) anunció hoy que su filial, Venture Global Calcasieu Pass, LLC (“VGCP”) ha cerrado su oferta de de dólares de monto principal agregado de 3,875% de pagarés sénior garantizados con vencimiento en 2033 (las “Notas “). Los Bonos vencerán el 1 de noviembre de 2033.

VGCP tiene la intención de utilizar los ingresos netos de la oferta para (i) pagar por adelantado ciertos montos pendientes de acuerdo con las líneas de crédito de primer gravamen garantizado sénior existentes de VGCP (las “Líneas de crédito existentes”), (ii) pagar los costos de rotura y terminación de la cobertura en relación con dicho pago anticipado y (iii) pagar honorarios y gastos relacionados con la oferta. Las notas están garantizadas por TransCameron Pipeline, LLC (filial de VGCP). Los Bonos están garantizados pari passu por una garantía mobiliaria de primera prioridad en los activos que aseguran las Líneas de Crédito Existentes y los bonos sénior garantizados existentes de VGCP al 3,875% con vencimiento en 2029 y al 4,125% en bonos sénior garantizados con vencimiento en 2031.

Las Obligaciones Negociables no se registraron bajo la Ley de Valores de 1933, según enmendada (la “Ley de Valores”) o las leyes de valores de ningún estado u otras jurisdicciones, y las Obligaciones Negociables no pueden ofrecerse ni venderse en los Estados Unidos sin el registro bajo los Valores Ley o una exención aplicable de los requisitos de registro de la Ley de Valores. Este comunicado de prensa no constituirá una oferta para vender o una solicitud de una oferta para comprar los Bonos, ni habrá ninguna venta de estos valores en ninguna jurisdicción en la que dicha oferta, solicitud o venta de estos valores sea ilegal antes del registro o calificación bajo las leyes de valores de dicha jurisdicción.

Acerca de Venture Global 

Venture Global es un proveedor de GNL de bajo costo y a largo plazo de los Estados Unidos que se abastece de las cuencas de gas natural norteamericanas, ricas en recursos. En la actualidad, Venture Global está construyendo o desarrollando más de 70 MTPA de capacidad de producción en Luisiana para proporcionar energía limpia y asequible al mundo.

Declaraciones prospectivas

Este comunicado de prensa contiene ciertas declaraciones que pueden incluir “declaraciones prospectivas”.  Todas las declaraciones incluidas en el presente documento que no sean declaraciones de hechos o condiciones históricos o presentes son “declaraciones prospectivas”.  Entre las “declaraciones prospectivas” se incluyen, entre otras cosas, declaraciones sobre la estrategia comercial, planes y objetivos de Venture Global, incluido el uso de los ingresos de la oferta.  Venture Global considera que las expectativas reflejadas en estas “declaraciones prospectivas” son razonables, intrínsecamente inciertas e implican una serie de riesgos e incertidumbres más allá del control de Venture Global. Además, las suposiciones pueden ser imprecisas. Los resultados reales pueden diferir sustancialmente de aquellos previstos o implícitos en las “declaraciones prospectivas” como consecuencia de una variedad de factores. Estas “declaraciones prospectivas” se refieren únicamente a la fecha en que se emitieron y, salvo que la ley lo exija, Venture Global no asume obligación alguna de actualizar o revisar cualquier “declaración prospectiva” o de proporcionar razones por las cuales los resultados reales puedan diferir, ya sea como resultado de información nueva, eventos futuros o de otro tipo.

Logo –

SOURCE Venture Global LNG, Inc.

Venture Global gibt den Abschluss einer vorrangig gesicherten Anleihe in Höhe von $ durch Venture Global Calcasieu Pass, LLC bekannt

ARLINGTON, Va., 23. November 2021 /PRNewswire/ — Venture Global LNG, Inc. („Venture Global”) gab heute bekannt, dass ihre Tochtergesellschaft Venture Global Calcasieu Pass, LLC („VGCP”) ihr Angebot von 3,875 % vorrangig besicherten Anleihen mit Fälligkeit 2033 (die „Anleihen”) in Höhe von insgesamt $ abgeschlossen hat. Die Anleihen werden am 1. November 2033 fällig.

VGCP beabsichtigt, den Nettoerlös aus dem Angebot zu verwenden, um (i) bestimmte ausstehende Beträge im Rahmen der bestehenden vorrangigen besicherten First-Lien-Kreditfazilitäten von VGCP (die „bestehenden Kreditfazilitäten”) im Voraus zu zahlen, (ii) Bruch- und Sicherungskündigungskosten im Zusammenhang mit einer solchen Vorauszahlung zu zahlen und (iii) Gebühren und Auslagen im Zusammenhang mit dem Angebot zu zahlen. Die Anleihen werden von TransCameron Pipeline, LLC (einer Tochtergesellschaft von VGCP) garantiert. Die Schuldverschreibungen sind durch ein erstrangiges Sicherungsrecht an den Vermögenswerten, die die bestehenden Kreditfazilitäten und die bestehenden vorrangig besicherten Schuldverschreibungen von VGCP in Höhe von 3,875 % mit Fälligkeit 2029 und 4,125 % mit Fälligkeit 2031 sichern, gleichrangig besichert.

Die Schuldverschreibungen wurden nicht gemäß dem Securities Act von 1933 in der jeweils gültigen Fassung (der „Securities Act”) oder den Wertpapiergesetzen eines Bundesstaates oder einer anderen Rechtsordnung registriert und dürfen in den Vereinigten Staaten nicht angeboten oder verkauft werden, es sei denn, sie sind gemäß dem Securities Act registriert oder von den Registrierungsanforderungen des Securities Act ausgenommen. Diese Pressemitteilung stellt weder ein Angebot zum Verkauf noch eine Aufforderung zum Kauf dieser Schuldverschreibungen dar, noch darf ein Verkauf dieser Schuldverschreibungen in einer Jurisdiktion erfolgen, in der ein solches Angebot, eine solche Aufforderung oder ein solcher Verkauf der Schuldverschreibungen vor der Registrierung oder Qualifizierung gemäß den Wertpapiergesetzen einer solchen Jurisdiktion ungesetzlich wäre.

Informationen zu Venture Global

Venture Global ist ein langfristiger, kostengünstiger Anbieter von US-amerikanischem LNG, das aus ressourcenreichen nordamerikanischen Erdgasvorkommen bezogen wird. Derzeit baut oder erschließt Venture Global 70 MTPA Produktionskapazität in Louisiana, um der Welt saubere Energie zu günstigen Preisen zu liefern.

Zukunftsgerichtete Aussagen

Diese Pressemitteilung enthält Aussagen, die „zukunftsgerichtete” Aussagen beinhalten können. Alle hierin enthaltenen Aussagen, die keine historischen oder aktuellen Fakten oder Gegebenheiten darstellen, sind „zukunftsgerichtete Aussagen”. Zu den „zukunftsgerichteten Aussagen” gehören unter anderem Aussagen zur Geschäftsstrategie, den Plänen und Zielen von Venture Global, einschließlich der Verwendung der Erlöse aus dem Angebot. Zwar ist Venture Global der Ansicht, dass die in diesen „zukunftsgerichteten Aussagen” zum Ausdruck gebrachten Erwartungen angemessen sind, dennoch sind sie von Natur aus unsicher und beinhalten eine Reihe von Risiken und Ungewissheiten, die außerhalb der Kontrolle von Venture Global liegen. Darüber hinaus kann es sich herausstellen, dass die Annahmen nicht richtig waren. Die tatsächlichen Ergebnisse können aufgrund einer Vielzahl von Faktoren wesentlich von jenen abweichen, die in den „zukunftsgerichteten Aussagen” erwartet oder impliziert werden. Diese „zukunftsgerichteten Aussagen” beziehen sich nur auf den Zeitpunkt des Abschlusses, und Venture Global ist nicht dazu verpflichtet, die „zukunftsgerichteten Aussagen” zu aktualisieren oder zu überarbeiten oder Gründe dafür anzugeben, warum die tatsächlichen Ergebnisse aufgrund neuer Informationen, zukünftig eintretender Ereignisse oder anderweitig, abweichen können.

Logo –

SOURCE Venture Global LNG, Inc.

Certified B Corp™ National Energy Improvement Fund Launches Fifth Round of Climate-Action Investment Opportunity for Retail Investors

ALLENTOWN, Pa. and DENVER, Nov. 23, 2021 /PRNewswire/ — The National Energy Improvement Fund, LLC (NEIF), a Certified B-Corp™ energy efficiency and resilience improvement lender, has launched the fifth round of a highly successful investment program targeted at smaller ticket investors who wish to earn a fixed return while helping fund NEIF’s mission of financing the transition to efficient and resilient homes and businesses. The four previous rounds all exceeded their targets.

Climate Action Investment Certificates are offered under Regulation CF through RaiseGreen, Inc, an SEC and FINRA licensed Funding Portal. They have a minimum investment level of $1,000 and pay a 7% annual return with twenty-eight scheduled quarterly payments. Full details of the offering can be found at

“We are excited to be able to continue to broaden the audience for investment in clean energy and building resilience,” said Peter Krajsa, NEIF Co-Chair and founder. “It’s an opportunity for investors to take direct action improving local resilience and sparking economic growth at a crucial moment in our political and social economy,” added Matthew Brown, NEIF Co-Chair and Founder.

NEIF’s work in climate impact was recently featured on the RaiseGreen podcast and on NPR affiliate WDIY

About the National Energy Improvement Fund
The National Energy Improvement Fund has a lending legacy from 1947 and was organized in 2017 as a for-profit Benefit Corporation, operating as a full-service, multi-state licensed consumer and commercial lender. It has funded over 5,000 energy and resilience improvements for HVAC, roofing, lighting and battery storage for homes and businesses delivered through a network of over 1,000 qualified contractors. Led by energy financing pioneers Peter Krajsa and Matthew Brown and a team responsible for over $800 million in energy financing programs, it received its certification as a B Corporation® in 2018 and was named a U.S. Department of Energy Home Improvement Expert™ Partner in 2019. It acquired the MyStrongHome insurance and resilience platform in 2020.

Media Contacts
Peter Krajsa, Co-Chair and Founder [email protected] / 610-737-4977
Matthew Brown, Co-Chair and Founder [email protected]

SOURCE National Energy Improvement Fund

Related Links

BeiGene Launches Proposed Initial Public Offering on the STAR Market in China

CAMBRIDGE, Mass. & BEIJING–()–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the commencement of an initial public offering (STAR Offering) on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange (SSE). The total number of shares being offered in the STAR Offering is 115,055,260 ordinary shares, par value $0.0001 per share, which represents 8.62% of BeiGene’s total outstanding ordinary shares as of October 31, 2021, after giving effect to the shares being offered. The shares offered in the STAR Offering (RMB Shares) will be issued to and subscribed for by permitted investors in the People’s Republic of China (PRC) and listed and traded on the STAR Market in Renminbi. In addition, BeiGene expects to grant China International Capital Corporation Limited a 30-day overallotment option for up to 17,258,000 additional RMB Shares. The consummation of the STAR Offering is subject to, among other things, market conditions, and there can be no assurance as to whether or when the STAR Offering may be completed, or as to the actual size or terms of the STAR Offering.

China International Capital Corporation Limited and Goldman Sachs Gao Hua Securities Co. Ltd. are acting as joint sponsors and joint bookrunners for the STAR Offering. J.P. Morgan Securities (China) Company Limited, CITIC Securities Co., Ltd. and Guotai Junan Securities Co., Ltd. are acting as joint bookrunners for the STAR Offering.

BeiGene expects to use the net proceeds from the STAR Offering to fund its research and clinical development, construction of its research and development centers and a manufacturing plant in China, sales and marketing force expansion in China, and for working capital and general corporate purposes.

In accordance with applicable PRC laws and regulations, the STAR Offering will be conducted solely within the PRC and only to permitted investors who are eligible to participate in the STAR Offering in accordance with applicable PRC securities laws and regulations, and rules promulgated by the SSE and the China Securities Regulatory Commission (CSRC). The STAR Offering will be conducted pursuant to a prospectus and other offering materials prepared by BeiGene in Chinese language and as approved by and registered with the SSE and the CSRC, which are only permitted to be used within the PRC. No part of the STAR Offering is intended to involve a public offering or sale of the RMB Shares into or in the United States or any other jurisdiction outside of the PRC. In addition, although the RMB Shares are of the same class and have the same rights as the Company’s existing ordinary shares listed on the Hong Kong Stock Exchange (HKEx), the RMB Shares will not be fungible with the ordinary shares listed on the HKEx or the Company’s American Depositary Shares (ADSs) representing its ordinary shares listed on the NASDAQ Global Select Market (NASDAQ), and in no event will any RMB Shares be able to be converted into ordinary shares listed on the HKEx or ADSs listed on NASDAQ, or vice versa.

An automatically effective shelf registration statement on Form S-3 was filed with the Securities and Exchange Commission (SEC) on May 11, 2020. A preliminary prospectus supplement relating to and describing the key terms of the STAR Offering will be filed with the SEC and will be available on the SEC’s website at The final terms of the STAR Offering will be disclosed in a final prospectus supplement to be filed with the SEC. The purpose of the prospectus supplement is to register all RMB Shares offered in the STAR Offering under the Securities Act of 1933, as amended (Securities Act), to ensure that the offer and sale of the RMB Shares, if any, to permitted investors who are U.S. persons (as defined in Regulation S under the Securities Act) in transactions outside the United States will not violate the registration requirements under Section 5 of the Securities Act.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to, and in accordance with, Rule 134 under the Securities Act.

About BeiGene

BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 7,700 colleagues across five continents. To learn more about BeiGene, please visit and follow us on Twitter at @BeiGeneGlobal.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including BeiGene’s current intentions, expectations or beliefs regarding the STAR Offering, including its expectations regarding the completion, size or terms of the STAR Offering, its expectations with respect to granting a 30-day overallotment option for up to 17,258,000 additional RMB Shares, and its expectations regarding the use of proceeds. These statements may be preceded by, followed by or include the words “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “likely,” “outlook,” “plan,” “potential,” “project,” “projection,” “seek,” “can,” “could,” “may,” “should,” “would,” “will,” the negatives thereof and other words and terms of similar meaning. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties related to completion of the STAR Offering on the anticipated terms or at all, market conditions and the satisfaction of customary closing conditions related to the STAR Offering. More information about the risks and uncertainties faced by BeiGene is contained or incorporated by reference in the preliminary prospectus supplement related to the STAR Offering filed with the SEC. Forward-looking statements include all statements that are not historical facts. There is no assurance that any forward-looking statements will materialize. You are cautioned not to place undue reliance on forward-looking statements, which reflect expectations only as of this date. BeiGene does not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise.

Premier Group Insurance, Inc. Announces New Agency Acquisition Program

DENVER, Nov. 23, 2021 /PRNewswire/ — Premier Group Insurance Inc., (PGI), is a leading Property & Casualty agency group with headquarters based in the greater Denver, Colorado area, with more than 500 Agency Owner members coast-to-coast and is one of the largest writers of Auto Home and Business insurance in the U.S.

In keeping with Premier’s “So Much More” support program for member agencies, Premier will be acquiring P & C agencies for and in tandem with existing Premier Agency owners.  

“This is a win-win for independent agencies looking to sell, to maximize their value and equity, and to place their agency in the best of like-hands, who are local so that policyholders and staff can continue the fine work and the legacy of the selling agency,” Rex Hickling, Premier’s President remarked. 

“PGI agency owners benefit from Premier’s strong balance sheet and 20+ years of retail agency experience and hands-on know-how, enabling Premier to take on this endeavor and drive Premier Owner Agency growth even higher, both organically and through acquisition,” said Chase McCool, Premier’s Vice President, who will head up the acquisition program. 

“This is compelling and exciting on so many fronts. There is a trust factor for Selling Agencies who sell to Premier as they benefit from local representation and continuity from Premier’s national agency footprint. And more importantly, a mindset to custom tailor an approach to each selling agency owner,” added Shawn Walker, Premier’s Senior Vice President.

“This includes a range of offerings to fit a seller’s situation best, to maintain and grow the business. For some, that may mean cash out, full or partial, business perpetuation options, and even existing employees or family members taking over the business with Premier’s capital help. At the end of the day, we say what we will do and then do what we say. For more than 20 years agents and policyholders alike have appreciated that simple clarity and follow-through,” said Premier’s CEO & Founder, Youngdon Yun. “That is Premier.”

If you’re an agency with a premium in Property and Casualty of $2,000,000 to $20,000,000 please feel free to reach out to us for a friendly confidential conversation.

In as little as 30 minutes we can give you an idea of your agency valuation and also tap into your needs and concerns from a financial and legacy standpoint and discuss what’s important to you for the perpetuation of the business and the care of your policyholders and staff.

Contact Premier at [email protected] to find out more.

“Own Your Tomorrow with Premier Today.”

[Contact info]
Premier Group Insurance
Rex Hickling
[email protected]

SOURCE Premier Group Insurance

Alpine 4 Holdings, Inc. Prices $24 Million Registered Direct Offering

PHOENIX, Nov. 23, 2021 /PRNewswire/ — Alpine 4 Holdings, Inc. (Nasdaq: ALPP), a leading operator and owner of small market businesses, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of  8,571,430  shares of the Company’s common stock (the “Shares”) and warrants to purchase 4,285,715 shares of the Company’s common stock (the “Warrants”, and together with the Shares, the “Securities”) at a combined purchase price of $2.80 per one Share and accompanying one-half Warrant pursuant to a registered direct offering.  The Warrants will have an exercise price of $3.10 per share, will be exercisable immediately, and will expire five years following the issuance date. The closing of the offering is expected to occur on or about November 26, 2021, subject to the satisfaction of customary closing conditions.

A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.

This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-252539) previously filed with the U.S. Securities and Exchange Commission (the “SEC“). A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

For further details of this transaction, please see the Form 8-K to be filed with the SEC. 

About Alpine 4 Holdings: Alpine 4 Holdings, Inc. (ALPP) is a NASDAQ traded conglomerate that acquires businesses that fit into its disruptive DSF business model of Drivers, Stabilizers, and Facilitators. At Alpine 4, we understand the nature of how technology and innovation can accentuate a business. Our focus is on how the adaptation of new technologies, even in brick-and-mortar businesses, can drive innovation. We also believe that our holdings should benefit synergistically from each other, have the ability to collaborate across varying industries, spawn new ideas, and create fertile ground for competitive advantages.

Four principles at the core of our business are Synergy. Innovation. Drive. Excellence. At Alpine 4, we believe synergistic innovation drives excellence. By anchoring these words to our combined experience and capabilities, we can aggressively pursue opportunities within and across vertical markets. We deliver solutions that not only drive industry standards, but also increase value for our shareholders. 


Investor Relations
[email protected] 

Forward-Looking Statements: Certain statements and information in this press release may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995.  The information disclosed in this press release is made as of the date hereof and reflects Alpine 4 most current assessment of its historical financial performance. Actual financial results filed with the SEC may differ from those contained herein due to timing delays between the date of this release and confirmation of final audit results. These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors the Company identifies from time to time in its filings with the SEC. Although Alpine 4 believes that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Alpine 4 disclaims any intention or obligation to update the forward-looking statements for subsequent events.

SOURCE Alpine 4 Holdings, Inc.